Public donation
There is no cost to the donating parents. However, only certain hospitals work with public cord blood banks. Families usually need to contact the bank before delivery, often between 28 and 34 weeks of pregnancy.
Cord Blood Awareness Month 2026: Build a Donation-to-Transplant Network
- Posted by Greg Wahlstrom, MBA, HCM
- Posted in 2026 Healthcare Observances Calendar, Health Observance Calendar
Skip to the executive brief
Link 01
Link 02
Link 03
Link 04
Link 05
Link 06
Donation-to-Transplant Network
Cord Blood Awareness Month 2026: Build a Donation-to-Transplant Network
Turn awareness into informed choice, reliable collection, equitable public inventory, strong quality controls, and transparent transplant access.
The leadership signal: a biological resource is only useful when the network works
July’s Cord Blood Awareness Month gives healthcare leaders a practical reason to review how expectant parents learn about cord blood, how donations are consented and collected, how units move to qualified banks, and how transplant programs access appropriate products. The purpose is not to pressure families toward one choice. It is to provide accurate, balanced information early enough for a real decision.
The Health Resources and Services Administration explains that blood remaining in the umbilical cord and placenta after birth contains blood-forming cells. These are not embryonic stem cells. Qualified cord blood units may help patients with leukemia, lymphoma, and certain inherited metabolic or immune-system disorders when a transplant is clinically appropriate.
Make the three pathways understandable before the delivery admission
HRSA describes three primary options. Public donation makes an eligible unit available to any compatible patient who may need a transplant. Family or private banking stores the unit for potential future use by the child or relatives and generally involves collection and ongoing storage fees. Directed donation may be available when a biological sibling has a diagnosed medical need. Availability, eligibility, timing, and costs differ, so hospitals should communicate the distinctions without promotional language.
The Food and Drug Administration also distinguishes products stored for personal or family use from units intended for unrelated recipients. Publicly banked unrelated products face additional regulatory requirements and generally must be licensed under a biologics license application or used under an investigational new drug pathway.
Protect every link in the collection and quality chain
Collection occurs after the baby is born and uses blood left in the umbilical cord and placenta. HRSA states that public donation does not change labor or delivery, and no blood is taken from the baby. A maternal blood sample is generally obtained for infectious-disease testing. The unit must then meet collection, transport, processing, testing, tissue-typing, cell-count, contamination, documentation, and storage requirements.
Inform
Offer balanced, accessible information during prenatal care.
Consent
Complete eligibility, health history, privacy, and use permissions.
Collect
Use trained staff and validated kits after birth.
Transport
Protect identity, timing, temperature, and chain of custody.
Qualify
Confirm cell dose, testing, sterility, and bank standards.
Connect
List suitable units for patient searches and transplant access.
Not every collected unit meets transplant standards. HRSA notes that insufficient blood-forming cells, contamination, or delayed delivery to the bank can prevent storage. With appropriate consent, some units may support research. Families should know these possibilities before collection rather than discovering them afterward.
Six executive decisions for a credible hospital program
1. Decide what your hospital can actually offer
Confirm whether the organization collects for public banks, private banks, directed donation, research, or a defined combination. Publish an accurate service map for clinicians and patients. If public donation is unavailable, provide neutral information on where it is offered rather than implying that private storage is the only option.
2. Move education upstream
Place information in prenatal workflows early enough for families to contact a bank, complete forms, and review eligibility. Provide interpretation, accessible formats, and consistent scripts. Labor admission is too late for most people to make a thoughtful, fully informed decision.
3. Standardize consent and privacy
Align obstetrics, legal, compliance, health information management, the collection team, and the bank. Explain potential transplant, research, or disposal pathways. Keep family identities protected and separate clinical documentation from bank-specific records according to applicable requirements.
4. Govern collection competency
Define who may collect, how competency is validated, how kits are stored, and what happens during urgent or unplanned births. Audit labeling, maternal samples, contamination, timing, packaging, and handoff. A well-intentioned collection that fails quality requirements creates burden without creating access.
5. Build equity into inventory strategy
HRSA emphasizes the need for donations from genetically varied communities because matching remains important and some patients struggle to find a suitable marrow donor. Partner with communities using trusted messengers and clear language. Do not reduce equity to targeted recruitment without also improving informed consent and access.
6. Separate evidence from marketing
Require claims about future use, regenerative medicine, or bank quality to match current FDA-authorized or approved uses and applicable regulation. FDA registration alone does not equal endorsement. Communications should distinguish established hematopoietic transplantation from speculative or unapproved uses.
Track access, quality, and experience as one scorecard
| Domain | Measure | Executive question |
|---|---|---|
| Education | Eligible prenatal patients receiving balanced information early enough to act | Which clinics, languages, or populations are missed? |
| Choice | Families documenting a voluntary, informed decision without sales pressure | Do patients understand public, private, and directed options? |
| Collection | Attempted collections completed without labeling, sample, or kit defects | Where does staff competency or readiness fail? |
| Transport | Units reaching the bank within required time and handling conditions | Are courier and after-hours processes dependable? |
| Quality | Units meeting bank criteria for storage and potential transplant use | Which defects are preventable at the hospital? |
| Equity | Participation, completion, and qualification stratified across populations | Does the program expand access without creating coercion? |
A 30-day activation plan
Days 1 to 10: Define
- Name an executive sponsor and operational owner.
- Confirm collection partners and available pathways.
- Map the prenatal-to-bank workflow and every consent point.
- Review all patient materials for accuracy and neutrality.
Days 11 to 20: Test
- Run a tabletop exercise for an after-hours collection.
- Audit kits, labels, maternal samples, and courier readiness.
- Observe how staff explain public and private options.
- Invite patient and community partners to critique the process.
Days 21 to 30: Govern
- Launch the access and quality dashboard.
- Review failed or discarded collections for preventable causes.
- Assign action owners and completion dates.
- Report changes back to clinicians and patient advisors.
Conclusion: treat awareness as network accountability
Cord Blood Awareness Month should help families make informed choices and help hospitals test whether their collection promises are operationally real. The strongest program combines accurate prenatal education, voluntary consent, trained collection, reliable transport, quality governance, equitable public inventory, and responsible transplant communication.
For executives, the standard is straightforward. Say clearly what your organization can offer, measure whether the network works, and correct every avoidable failure that prevents a qualified unit from becoming a potential treatment option.
Resources and connected guidance
Authoritative external sources
The Healthcare Executive resources
Clinical note: This executive brief supports governance and patient education. It does not replace current transplant guidance, bank requirements, regulatory obligations, or patient-specific medical advice.
